Kenvue Inc. (NYSE:KVUE) Shares Sold by Cooke & Bieler LP

Cooke & Bieler LP reduced its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 99.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,993 shares of the company's stock after selling 2,681,477 shares during the period. Cooke & Bieler LP's holdings in Kenvue were worth $384,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Pittenger & Anderson Inc. purchased a new stake in shares of Kenvue during the 1st quarter valued at about $30,000. TruNorth Capital Management LLC purchased a new stake in Kenvue during the first quarter valued at approximately $36,000. Continuum Advisory LLC lifted its stake in shares of Kenvue by 2,071.1% in the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock valued at $47,000 after purchasing an additional 1,864 shares during the last quarter. Clarity Asset Management Inc. bought a new stake in shares of Kenvue in the 4th quarter valued at approximately $45,000. Finally, Rossby Financial LCC purchased a new position in shares of Kenvue in the 1st quarter worth approximately $52,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on KVUE. Bank of America dropped their price objective on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday. Citigroup dropped their price target on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating for the company in a research note on Tuesday. Redburn Atlantic assumed coverage on shares of Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective on the stock. Evercore ISI assumed coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective for the company. Finally, UBS Group cut their target price on Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research note on Thursday. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Kenvue has an average rating of "Hold" and a consensus price target of $24.71.

Kenvue Stock Up 0.7%

Shares of KVUE stock traded up $0.15 on Friday, hitting $22.00. The stock had a trading volume of 12,727,162 shares, compared to its average volume of 16,308,763. Kenvue Inc. has a one year low of $17.85 and a one year high of $25.17. The business has a 50 day moving average price of $22.20 and a 200 day moving average price of $22.30. The company has a market cap of $42.21 billion, a PE ratio of 40.00, a P/E/G ratio of 3.41 and a beta of 0.83. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The firm had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. During the same quarter in the previous year, the firm earned $0.28 EPS. The company's quarterly revenue was down 3.9% compared to the same quarter last year. Research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.